ABSTRACT
<p><b>OBJECTIVE</b>Chronic prostatitis, especially type III A, is a common disease in adult males, for which there are quite a few therapeutic methods. This study aimed to investigate the clinical efficacy of enoxacin in the treatment of III A prostatitis.</p><p><b>METHODS</b>We selected 198 cases of III A prostatitis with complete treatment and follow-up data from the outpatients, all treated by enoxacin injection for 1 week, followed by oral medication of enoxacin for 2 weeks. Then we evaluated the therapeutic effect based on the NIH-CPSI scores and changes in the indexes of expressed prostatic secretions (EPS).</p><p><b>RESULTS</b>The rate of total effectiveness was 86.4%, cure 8.6% (17/198), remarkable effectiveness 58.1% (115/198), improvement 19.7% (39/198), and ineffectiveness 13.6% (27/198). Only 16 cases (8.1%) complained of transitory gastrointestinal tract discomfort and/or skin itching.</p><p><b>CONCLUSION</b>Enoxacin has desirable efficacy and few adverse effects on type III A prostatitis.</p>
Subject(s)
Adult , Humans , Male , Middle Aged , Young Adult , Anti-Infective Agents , Therapeutic Uses , Chronic Disease , Enoxacin , Therapeutic Uses , Prostatitis , Drug Therapy , Treatment OutcomeABSTRACT
Fluoroquinolones are an important group of antimicrobial agents that are used widely in the treatment of various infectious diseases. The purpose of the present study was to synthesize new N-piperazinyl quinolone derivatives with 5-chloro-2-theinyl group having possible antimicrobial activity. Reaction of ciprofloxacin [1], norfloxacin [2] and enoxacin [3] with alpha-bromoketone 10 or alpha-bromooxime derivatives 11a-c in DMF, in the presence of NaHCO[3] at room temperature, afforded corresponding ketones 4a-c or oxime derivatives 5-7[a-c], respectively. The synthesized compounds were tested against a series of Gram-positive and Gram-negative bacteria. The results of MIC tests against both Gram-positive and Gram-negative bacteria revealed that ciprofloxacin derivatives [compounds 4a, 5a, 6a and 7a] were more active than norfloxacin and enoxacin analogues. Compound 5a, containing N-[2-[5-chlorothiophen-2-yl]-2-hydroxyiminoethyl] residue provided a high in vitro antibacterial activity against Gram-positive bacteria, with MIC of 0.06, 0.125, 0.5 and 0.125 micro g/mL against S. aureus, S. epidermidis, E. feacalis and B. subtilis, respectively. Its activity was found to be 4 to 8 times better than reference drug [ciprofloxacin] against all Gram-positive bacteria with the exception of E. feacalis
Subject(s)
Fluorometholone , Ciprofloxacin/analogs & derivatives , Ciprofloxacin , Norfloxacin/analogs & derivatives , Norfloxacin , Enoxacin/analogs & derivatives , Enoxacin , KetonesABSTRACT
Lung cancer is the leading cause of cancer- related death in the world today. Since the effective management of drug resistant lung cancer, and particularly non-small cell lung carcinomas is a major problem, attempts need to be made to identify new potential anticancer drugs that can kill non-small cell lung cancer cells efficiently. In the present study, a human non-small cell lung carcinoma NCI-H460 cell line was used to evaluate the antiproliferative activity of Fluoroquinolones like Enoxacin, Norfloxacin, Ciprofloxacin and Levofloxacin. As determined by Sulphorodhamine B assay (SRB assay), all Fluoroquinolones caused cellular growth inhibition in a concentration and time-dependent manner. Enoxacin was found to be the most effective Fluoroquinolone followed by Norfloxacin, Ciprofloxacin and Levofloxacin. Growth inhibitory effects were also found to be independent of the concentrations of serum growth factors in culture medium or variation of initial cell seeding density and proved to be irreversible in nature. Appearance of rounded cells with altered morphology and cell surface blebbing indicated cell killing by apoptosis. Cell shrinkage, nuclear condensation & fragmentation, and cytoplasmic blebbing as indicated by MGG staining confirmed this to be the case. Thus, this investigation clearly demonstrated that the NCI-H460 human non-small cell lung carcinoma cell line is highly sensitive to Fluoroquinolone treatment. The Fluoroquinolones used in this study which are clinically used as antibacterial agents, can also inhibit tumor cell growth suggesting their potential use in a strategy for cancer treatment which might help in controlling cancer.
Subject(s)
Apoptosis/drug effects , Carcinoma, Non-Small-Cell Lung , Cell Division/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Cells, Cultured , Ciprofloxacin/pharmacology , Dose-Response Relationship, Drug , Enoxacin/pharmacology , Evaluation Studies as Topic , Fluoroquinolones/pharmacology , Humans , Lung/cytology , Lung Neoplasms , Norfloxacin/pharmacology , Ofloxacin/pharmacology , Probability , Reference ValuesABSTRACT
<p><b>AIM</b>To analyze the response factors of different quinolone antibiotics detected by evaporative light-scattering detector (ELSD).</p><p><b>METHODS</b>The response factors of five different quinolones (enoxacin, levofloxacin, ciprofloxacin, lomefloxacin and gatifloxacin) detected by ELSD were determined by using a YMC-Pack ODS-AM cloumn (150 mm x 4.6 mm ID, 5 microns) as analytical column and 0.5% triethylamine (adjusting pH 2.5 with trifluoroacetic acid)-acetonitrile (48:12) as mobile phase at a flow rate of 0.6 mL.min-1, the temperature of the drift tube was set at 117 degrees C, and the flow of carrier gas at 3.0 L.min-1. Detector responses (A) and the amount of injection of each substance (m) were fitted to the logarithmic regression: log A = b log m + log a.</p><p><b>RESULTS</b>The linear regression equation obtained were: enoxacin: Y = 1.0799X + 2.7611, r2 = 0.9996; levofloxacin: Y = 1.0913X + 2.7235, r2 = 0.9997; ciprofloxacin: Y = 1.0828X + 2.7523, r2 = 0.9994; lomefloxacin: Y = 1.0891X + 2.7391, r2 = 0.9993; gatifloxacin: Y = 1.0878X + 2.7392, r2 = 0.9995. The differences between them were negligible.</p><p><b>CONCLUSION</b>Different quinolones can give the same responses with ELSD detection. So, the HPLC-ELSD methods can be applied to the determination of new substances by using another substance as reference.</p>
Subject(s)
Chromatography, High Pressure Liquid , Methods , Ciprofloxacin , Enoxacin , Fluoroquinolones , Levofloxacin , Light , Linear Models , Ofloxacin , QuinolonesABSTRACT
<p><b>AIM</b>To study the synthesis and antibacterial activity of pyridonecarboxylic acid derivatives containing 2-methyl-5-nitroimidazol.</p><p><b>METHODS</b>Pyridonecarboxylic acid derivatives containing 2-methyl-5-nitroimidazol were synthesized primarily from 2-methyl-5-nitroimidazol, norfloxacin, ciprofloxacin, enoxacin via nucleophilic substitution and esterification. The antibacterial activity of the nine target compounds were tested.</p><p><b>RESULTS</b>Nine new compounds were synthesized (IIa-c and IIIa-f). The structure of the title compounds were identified by 1HNMR, MS as well as elementary analysis.</p><p><b>CONCLUSION</b>Compounds IIa, IIb and IIc showed antibacterial activity, and were worth further studying.</p>
Subject(s)
Animals , Female , Mice , Anti-Infective Agents , Chemistry , Pharmacology , Ciprofloxacin , Pharmacology , Combinatorial Chemistry Techniques , Methods , Enoxacin , Pharmacology , Escherichia coli , Microbial Sensitivity Tests , Molecular Structure , Nitroimidazoles , Chemistry , Norfloxacin , PharmacologyABSTRACT
One hundred and thirty strains of Salmonella typhi were isolated from the blood of patients clinically suspected to be suffering from typhoid fever for the 5-year period from Jan 1995 to Dec. 2000. The blood cultures were taken in brain heart infusion broth. The isolates were identified based on morphological, biochemical and serological characteristics. The susceptibility of the strains was tested by disc diffusion tests as per standard methods. A high level of resistance to first-line drugs was observed. 43.85 percent strains of S. typhi revealed resistance to chloramphenicol, 42.3 percent to ampicillin, 46.15 percent to co-trimoxazole, 37.69 percent to Amoxicillin, 6.15 percent to ciprofloxacin, 0.77 percent to pefloxacin, enoxacin, and ofloxacin. No resistance to ceftriaxone and cefotaxime was observed
Subject(s)
Humans , Male , Female , Drug Resistance, Microbial , Typhoid Fever/drug therapy , Chloramphenicol/pharmacology , Ciprofloxacin , Ofloxacin , Pefloxacin , Enoxacin , Cefotaxime , Ceftriaxone , Drug Resistance, MultipleABSTRACT
A preparation of water soluble components(EA) was made from carpophores of Elfvingia applanata(Pers.) Karst and its in vitro antibacterial activity on a number of bacterial species was examined by macrobroth dilution assay. Among 16 species of bacteria tested, the most potent antibacterial activity was observed against Staphylococcus epiderrnidis and Proteus vulgaris, of which MICs were 1.25 mg/ml. To investigate the antibacterial effects in combinations of EA with quinolone antibiotics, such as ciprofloxacin, enoxacin, lomefloxacin, norfloxacin, and ofloxacin, the fractional inhibitory concentrations(FICs) and the fractional inhibitory concentration indices(FICIs) for four bacterial strains were determined by macrobroth dilution checkerboard assay. Combinations of EA and quinolones exhibited either additive or indifferent effects of antibacterial activity in most instances. However, both synergistic and antagonistic effects were not observed in any cases.
Subject(s)
Anti-Bacterial Agents , Bacteria , Ciprofloxacin , Enoxacin , Norfloxacin , Ofloxacin , Proteus vulgaris , Quinolones , StaphylococcusABSTRACT
BACKGROUND: The photsensitizing effect of quinolones has been recognized since their introdulation as an antibacterial agents. Recently several new second eneration antibacterial agents of this pharmacological class have become available for therapy, and are gaining increasing impotance. OBJECTIVE: To reveal the phototoxic potentials of some new quinolones by photohemolysis test, estimation of fluorescenc spectra, and Candida albicans test. METHODS: Nalidixic acid and four second-generation quinolones(ciprofloxacin, enoxacini, norfloxacin, and ofloxacitid were examined by fluorescence spertra which measured t.he phototoxc potentials by photochemial instability, photohemolsis test for the phototoxic properties against cell membranes and Candida tlbicans test for phototoxic properties against DNA. RESULTS: All drugs showed a fluorescence spectra within 360 nm to 450 nm, and in the photohemolysis test, all studied drug except ofloxacin got above 5% hemolytic value, and all drugs showed clear zone. in Candida albicans test after 48hours. CONCLUSION: These results suggested that all tested drugs were photochemically unstable. According to the mechanisris of cellular phototoxicity, ciprofloxacin, enoxacin, and norfloxacin was phtototoxic to nucleus and cell membrane, whereas ofloxacin was phototoxic to nucleus only.
Subject(s)
Anti-Bacterial Agents , Candida , Candida albicans , Cell Membrane , Ciprofloxacin , Dermatitis, Phototoxic , DNA , Enoxacin , Fluorescence , Nalidixic Acid , Norfloxacin , Ofloxacin , QuinolonesABSTRACT
Se determinó la actividad in vitro de 6 fluroquinolonas, ciprofloxacina (Cip), enoxina (Eno), fleroxacina (Fle), lomefloxacina (Lome), norfloxacina (Nor) y pefloxacina (Pef) sobre 320 cepas clínicas de bacilos gram negativos y staphylococcus, aisladas de 2 centros asistenciales de Antofagasta. Se utilizó una técnica de dilución en placa. Las 6 quinolonas mostraron muy buena actividad sobre escherichia coli con una CMI menor a 0,03 ug/ml para Cip, Lome y Nor, y también frente klebsiella pneumoniae, con CIM entre 0,125 y 0,5 ug/ml, siendo las drogas de mejor actividad Cip y Lome. Comparativamente, la actividad in vitro de las quinolonas estudiadas fue inferior sobre pseudomonas aeruginosa, siendo las de mejor actividad Cip y Eno con una CMI50 entre 0,25 y 0,5 ug/ml. Las fluoroquinolonas estudiadas mostraron también una buena actividad frente a cepas de S. aureus, especialmente Nor y Cip, cuyas CMI correspondieron a 0,25 y 1 ug/ml. En cambio, para las cepas de staphylococcus coagulasa negativa las fluoroquinolonas mostraron una actividad inferior, ya que el 90 por ciento fue inhibida por 1 ug/ml de Cip y 8 ug/ml de Lome y Eno. De las 6 fluoroquinolonas estudiadas, ciprofloxacina y lomefloxacina resultaron de mejor actividad in vitro frente a cepas de E. coli, K. pneumoniae, P. aeruginosa, S. aureus y S. coagulasa negativas aisladas en Antofagasta
Subject(s)
Anti-Infective Agents/pharmacology , Escherichia coli/drug effects , In Vitro Techniques , Klebsiella pneumoniae/drug effects , Pseudomonas aeruginosa/drug effects , Staphylococcus/drug effects , Ciprofloxacin , Colony Count, Microbial , Drug Resistance, Microbial , Enoxacin , Escherichia coli/isolation & purification , Fleroxacin , Cross Infection/microbiology , Klebsiella pneumoniae/isolation & purification , Norfloxacin , Permissible Limit of Occupational Hazards , Pseudomonas aeruginosa/isolation & purification , Staphylococcus/isolation & purificationABSTRACT
Escherichia coli es uno de los bacilos gram negativos más aislados en nuestras clínicas, provocando diversos cuadros de tipo infeccioso. Por este motivo es importante conocer la susceptibilidad antimicrobiana de esta especie, con el fin de poder administrar drogas antimicrobianas realmente efectivas. Este trabajo determina la sensibilidad cuantitativa "in vitro" de 245 cepas de Escherichia coli, aisladas de diversas muestras clínicas frente a 13 drogas antimicrobianas para lo cual se utilizó el método de dilución en agar de Ericsson y Sherris. Los resultados obtenidos muestran que alrededor del 90 por ciento de las cepas fueron sensibles a Enoxacino, Cefotaxima, Aztreonam, Gentamicina, Ceftriaxzona, Amikacina, Cefuroximo, Cefoperazona y Nitrofurantoina y alrededor del 50 por ciento de las cepas fueron sensibles a Cefradina. Frente a los restantes antimicrobianos-Cloramfenicol, Cotrimoxazol y Ampicilina- se obtuvo un alto nivel de resistencia
Subject(s)
Anti-Bacterial Agents/pharmacology , Escherichia coli Infections/drug therapy , Escherichia coli/drug effects , In Vitro Techniques , Amikacin/pharmacology , Ampicillin/pharmacology , Aztreonam/pharmacology , Cefoperazone/pharmacology , Cefotaxime/pharmacology , Ceftriaxone/pharmacology , Cefuroxime/pharmacology , Cephradine/pharmacology , Chloramphenicol/pharmacology , Drug Resistance, Microbial , Enoxacin/pharmacology , Gentamicins/pharmacology , Microbial Sensitivity Tests , Nitrofurantoin/pharmacologyABSTRACT
The susceptibilities of 45 clinical isolates of bacteroidis fragilis to cefaclor, ciproflxacin and imipenem were determined by new method, E-test (AB Bidisk, Solna, Sweden) and were compared with those from conventional agar dilution method by using brain heart infusion, Mueller-Hinton and Wilk:..s Chalgren agar plates. And the susceptibility of 60 clinical isolates of bacteroides fragilis group (B. fragilis 45 strains, B. distasonis 6 strains, B. ovatus 5 strains, B. thetaiotaomicron 4 strains) to 5 quinolones (ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin) were determined by in vitro agar dilution method. Compared with agar dilution MICs for B. fragilis 45 strains, 90.3% of E-test MICs were within +/- 1 dilution of the agar dilutions, and 98.4% were within 2 dilutions. And there were little effect of different medium bases to determine MICs except Mueller-Hinton agar. On Mueller-Hinton agar, B. fragilis showed have or no growth activity. In vitro susceptibility of B. fragilis group to quinolones, most of the test strains showed resistant patterns to quinolones except ofloxacin and there was little difference of susceptibility patterns between species of B. fragilis group.
Subject(s)
Agar , Bacteroides fragilis , Bacteroides , Brain , Cefaclor , Enoxacin , Heart , Imipenem , Norfloxacin , Ofloxacin , QuinolonesABSTRACT
No abstract available.
Subject(s)
Chlamydia trachomatis , Chlamydia , Doxycycline , Enoxacin , Erythromycin , Pipemidic AcidABSTRACT
No abstract available.
Subject(s)
Chlamydia trachomatis , Chlamydia , Doxycycline , Enoxacin , Erythromycin , Pipemidic AcidABSTRACT
Enoxacin, a new 6-fluoroquinolone known to be active in vitro against most common pulmonary pathogens, was evaluated in comparison with ceftazidime, a third generation cephalosporin proven to be effective in the treatment of gram negative pneumonias. Clinical and microbiologic responses to therapy were satisfactory and comparable in both antibiotic groups. Enoxacin could be an effective alternative choice in the treatment of lower respiratory tract infections caused by gram negative organisms.
Subject(s)
Adult , Ceftazidime/therapeutic use , Enoxacin/therapeutic use , Female , Gram-Negative Bacterial Infections/drug therapy , Hospitalization , Humans , Male , Middle Aged , Pneumonia/drug therapy , Prospective Studies , Sputum/microbiologyABSTRACT
One hundred and fifty strains of Gram negative bacilli isolated from urine of patients with urological disease were tested for resistance to antimicrobial drugs including quinolones. Escherichia coli (61 strains) was most frequently isolated, and followed by Klebsiella spp. (36), Pseudomonas aeruginosa (12). and Proteus spp. (6) in the decreasing order. New quinolone carboxylic acid compounds such as enoxacin (Ex). norfloxacin (Nf), ciprofloxacin (Cp), pefloxacin (Pf), and ofloxacin (Of) showed very high antimicrobial activities against the majority of organisms tested except P.aerogi. nose. In P.aeruginosa all strains were resistant to nalidixic acid, and 25-33% to Ex. Nf. Cp, Pf, and Or. The majority of strains tested were found to be resistant to beta-lactam antibiotics except moxalactam (Mr). aminoelycoside drugs except amikacin (Ak), and other drugs tested such as chloramphgnicol, tetracycline. rifampin and etc.. but in P.aeruginosa, 33-58% were resistant to Mx and Ak. Organisms multiplyine resistance to 5 or more druge were noted in almost all isolates tested The stain numbers of multiplying resistance to 5 or more drugs were 51 strains (83.6%) of E. Coli 24 strains (66.7%) of Klebsielle spp., 10 strains (83.3%) of P.aeruginosa, and 5 strains (83.3%) of Prorteus spp.
Subject(s)
Humans , Amikacin , Anti-Bacterial Agents , Ciprofloxacin , Drug Resistance, Microbial , Enoxacin , Escherichia coli , Klebsiella , Moxalactam , Nalidixic Acid , Norfloxacin , Nose , Ofloxacin , Pefloxacin , Proteus , Pseudomonas aeruginosa , Quinolones , Rifampin , Tetracycline , Urologic DiseasesABSTRACT
Las infecciones crónicas de oído mastoides constituyen patologías de díficil tratamiento: en ellas encontramos infecciones mixtas y a veces resistentes a los antibioticos de uso oral. Enoxacin es una nueva quinolona de amplio espectro que ha demostrado eficacia contra gérmenes gram negativos incluída Pseudomonas aeruginosa. Nosotros estudiamos la eficacia de enoxacin oral en 26 pacientes con infecciones crónicas de oído y mastoides. Pueden según la necesidad asociarse a antibióticos antianaersbicos
Subject(s)
Enoxacin/therapeutic use , Mastoiditis/diagnosis , Ear, Middle/pathology , Otitis/diagnosisABSTRACT
Se trató 30 pacientes con diagnóstico de tuberculosis pulmonar con esquema de retratamiento que incluían Enoxacina en el Programa de Control de TBC del Hospital Nacional Cayetano Heredia y centros relacionados en Lima, Perú desde 1988. Los cuales recibieron el fármaco por razones humanitarias a una dosis de 10 mg/kg/dia en forma supervisada. Se seleccionaron 22 pacientes que cumplieron los criterios de inclusión. 20 tenían problemas clínico-bacteriológico de resistencia a drogas (incluyendo a la Rifampicina) y 2 habían presentado reacción adversa a todas las drogas de primera línea. Dos pacientes abandonaron luego del sexto mes de tratamiento, de los restantes; 7 (35 por ciento) negativizaron persistentemente el esputo, 5 (25 por ciento) de estos están actualmente de alta, 4 (20 por ciento) alternan baciloscopías positivas y negativas, y hasta el 70 por ciento negativizaron por lo menos en un control mensual. 2 (10 por ciento pacientes fallecieron. El estudio evaluativo empleó estadísticamente paramétrica y no paramétrica y se devidió en dos partes; La primera analizó los datos baciloscópicos en forma cualitativa, la evolución radiológica y los pesos en cada paciente comparando período previo y durante el uso de Enoxacina, la cual mostró una disminución significativa en la media de la positividad baciloscópica (p:0.001). Los índices evolutivos radiológicos aumentaron en forma significativa (p:0.001), evidenciando una mejoria radiológica. Hubo un aumento no significativo en los pesos (p:0.079). La segunda parte de la evaluación fue diseñada para analizar los datos baciloscópicos cuantitativos comparando ambos periodos, lo cual mostró una disminución significativa en la media del área bajo la curva (p:0.011), lo cual se traduciría en una disminución en la carga bacilar de los esputos. Los reultados nos permiten concluir que a los pacientes a quienes se le dió este fármaco dentro de sus esquemas que además incluían por lo general una o dos drogas nuevas de segunda línea, presentaron mejoría clínica radiológica. Por lo cual se sugiere profundizar los estudios para determinar el rol exacto de la Enoxacina en el tratamiento de la tuberculosis pulmonar
Subject(s)
Humans , Enoxacin/therapeutic use , Tuberculosis, Pulmonary/drug therapy , Peru , Sputum/chemistryABSTRACT
No abstract available.
Subject(s)
Humans , Ciprofloxacin , Enoxacin , Metabolism , TheophyllineABSTRACT
The in vitro susceptibility pattern with respect to lomefloxacin was determined in case of 1009 bacterial isolates from clinical specimens with varying susceptibility to commonly used antimicrobial agents. The MIC50 and MIC90 values of lomefloxacin for the Gram negative bacilli showed susceptibility value ranging between 0.12 to 4.0 micrograms/ml, while 90 per cent of the streptococci tested were inhibited only at 16 micrograms/ml. Lomefloxacin was comparable in activity to enoxacin and ciprofloxacin but it was more active than norfloxacin and nalidixic acid.